These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24602738)

  • 1. [Development of acute myeloid leukemia in a myelodysplastic syndrome patient after allogeneic hematopoietic stem cell transplantation for 12 years: a case report and literature review].
    Li Z; Zhang Y; Zhou J; Fang B; Lin Q; Song Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):63-5. PubMed ID: 24602738
    [No Abstract]   [Full Text] [Related]  

  • 2. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
    de Lima M; Giralt S
    Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Bernal T; Diez-Campelo M; Godoy V; Rojas S; Colado E; Alcoceba M; González M; Vidriales B; Sánchez-Guijo FM; López-Corral L; Luño E; del Cañizo C
    Leuk Res; 2014 May; 38(5):551-6. PubMed ID: 24655806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mini-transplant for acute myeloblastic leukemia and myelodysplastic syndrome].
    Kanda Y
    Nihon Rinsho; 2003 Sep; 61(9):1565-72. PubMed ID: 14515725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemia in donor cells after allogeneic hematopoietic stem cell transplant.
    Brunstein CG; Hirsch BA; Hammerschmidt D; McGlennen RC; Nguyen PL; Verfaillie CM
    Bone Marrow Transplant; 2002 Jun; 29(12):999-1003. PubMed ID: 12098070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of hematopoietic stem cell transplantation in acute myelogenous leukemia and myelodysplastic syndrome.
    Tallman MS; Mathews V; DiPersio JF
    Cancer Treat Res; 2009; 144():415-39. PubMed ID: 19779880
    [No Abstract]   [Full Text] [Related]  

  • 8. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
    Sill H; Zinke-Cerwenka W; Berghold A
    Bone Marrow Transplant; 2007 Apr; 39(8):509; author reply 509-10. PubMed ID: 17322936
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
    Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
    Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Gao L; Gao L; Gong Y; Zhang C; Chen XH; Zhang X
    Leuk Res; 2013 Nov; 37(11):1482-7. PubMed ID: 24054720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].
    Nakamura Y; Mori T; Kato J; Aisa Y; Nakazato T; Shigematsu N; Okamoto S
    Rinsho Ketsueki; 2012 Mar; 53(3):318-22. PubMed ID: 22499048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to engraftment following allogeneic stem cell transplantation is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia.
    Bitan M; Or R; Shapira MY; Resnick IB; Gesundheit B; Ackerstein A; Samuel S; Elad S; Slavin S
    Bone Marrow Transplant; 2008 Jan; 41(1):69-78. PubMed ID: 17994125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
    Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi QL; Minden M; Messner H; Kiss T
    Biol Blood Marrow Transplant; 2005 Oct; 11(10):764-72. PubMed ID: 16182177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.
    Lim Z; Brand R; Martino R; van Biezen A; Finke J; Bacigalupo A; Beelen D; Devergie A; Alessandrino E; Willemze R; Ruutu T; Boogaerts M; Falda M; Jouet JP; Niederwieser D; Kroger N; Mufti GJ; De Witte TM
    J Clin Oncol; 2010 Jan; 28(3):405-11. PubMed ID: 20008642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
    Valcárcel D; Martino R
    Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up.
    Shimoni A; Hardan I; Shem-Tov N; Yerushalmi R; Nagler A
    Leukemia; 2010 May; 24(5):1050-2. PubMed ID: 20147978
    [No Abstract]   [Full Text] [Related]  

  • 19. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
    Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
    Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.